September 15, 2023

Pliant Therapeutics

Pliant Therapeutics Appoints Minnie Kuo as Chief Development Officer

September 12, 2023


Septerna Announces Novel GCPR-targeted Program Acquired by Vertex

September 12, 2023

CARGO Therapeutics

CARGO Therapeutics Announces Appointments of Michael Ports, PhD, as Chief Scientific Officer

September 07, 2023

Rapport Therapeutics

Rapport Therapeutics appoints Chief Operating Officer and Scientific Advisory Board Memberr

September 07, 2023

Fulcrum Therapeutics

Fulcrum announces completion of enrollment in the Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophyfu

Load More

Sign up for weekly portfolio news.